Precision medicine market seen topping $456 billion by 2035

The global precision medicine market is projected to grow from $118.23 billion in 2025 to $456.81 billion by 2035, according to Market Research Future. The report points to national genomics programs, AI-enabled diagnostics and faster companion diagnostic review as the main forces behind the expansion.

Why it matters: - Precision medicine is moving from a niche clinical approach to a core part of drug selection, cancer care and genetic screening. - The market's projected growth signals more spending on genomics, diagnostics and data tools across hospitals, labs and drugmakers. - The shift could also reshape reimbursement, regulatory timelines and where healthcare systems invest over the next decade.

What happened: - Market Research Future projected the global precision medicine market will rise from $118.23 billion in 2025 to $456.81 billion by 2035. - The forecast implies a 14.72% compound annual growth rate from 2026 to 2035. - The firm estimated the market at $118.23 billion in 2025 and $134.10 billion in 2026. - The report tied growth to national genomics and biobank programs, AI and machine-learning diagnostics, and companion diagnostic regulatory reform. - North America held about 45% of the market in 2025, while Asia-Pacific was the fastest-growing region at more than 15.8% CAGR through 2035.

The details: - The U.S. All of Us Research Initiative has enrolled more than 800,000 participants. - Genomics England has completed 100,000 whole-genome sequences. - The U.S. program aims to sequence 1 million genomes with $3.1 billion committed. - China's National Genomics Data Center holds more than 3.8 petabytes of sequencing data. - The FDA approved 171 medical devices with AI/ML capabilities in 2024. - Tempus and Foundation Medicine analyze multi-omic patient profiles in less than 48 hours, helping guide cancer treatment selection. - The FDA's 2023 companion diagnostic guidance cut co-development review timelines from 12 months to about seven months. - The EMA introduced a parallel scientific advice framework in early 2024. - CMS expanded Medicare coverage for pharmacogenomic panel testing in 2024, covering more than 200 gene-drug interactions. - The report said that expansion could affect 60 million Medicare beneficiaries and add $4.2 billion in annual testing revenue by 2028. - Next-generation sequencing was the largest technology segment in 2025 with about 38% share. - AI and machine learning was the fastest-growing technology segment, projected at 19.3% CAGR through 2035. - Bioinformatics and big data analytics generated $28.4 billion in 2025 revenue. - Oncology led applications with 43.5% share in 2025. - Rare and genetic disorders were projected to grow at 17.1% CAGR. - Pharmaceutical and biotechnology companies held about 48% of end-user share in 2025. - Home-care settings were the fastest-growing end-user segment at 17.0% CAGR. - Hospitals and clinical laboratories generated $26.8 billion in 2025. - The U.S. Inflation Reduction Act and the EU Pharmaceutical Strategy were said to have earmarked more than $12 billion in incentives through 2030. - The report identified liquid biopsy, pharmacogenomics-as-a-service, AI-native decision support, personalized mRNA vaccines and emerging-market genomics infrastructure as future growth areas.

Between the lines: - The forecast suggests the market is being pulled by policy and infrastructure as much as by scientific progress. - Faster regulatory review and wider reimbursement could matter as much as new test technology in turning research into commercial revenue. - The regional split points to a mature North American market and a faster build-out phase in Asia-Pacific and emerging regions.

What's next: - The report expects the market to keep expanding as more national biobanks, payer coverage and AI tools reach routine care. - Precision medicine adoption is likely to deepen in oncology first, then spread further into primary care, neurology and infectious disease management. - Market Research Future said emerging-market genomics investments in India, Brazil and Southeast Asia will add demand for biomarker-driven therapies. - The company also pointed to a growing opportunity in home-care testing and decentralized genomic services.

The bottom line: - Precision medicine is entering a scale-up phase, with genomics data, AI diagnostics and reimbursement policy driving the next wave of growth.